

## CONGENITAL AFIBRINOGENAEMIA AND FAMILIAL COMBINED HYPERLIPIDAEMIA IN A KINDRED

A Najada, JMB, MRCP\*, MS Akasheh, MD, JMB\*\* S Eid, MSc\*\*\*, K Omari, MD, JMB\*\*  
F Madanat, MD, JMB\*\*, T Shubeilat, MD, JMB\*\*\* A Omeish, MD, LMB\*\*

We studied the correlation of fibrinogen and plasma lipids in a 9 months old Jordanian girl with afibrinogenaemic proposita. The study design was a pedigree analysis composed of three generations, and 31 individuals. Age, gender, plasma fibrinogen, total cholesterol, triglycerides, LDL-cholesterol was measured. Our proposita plasma fibrinogen was absent; in addition to hyperlipidaemia type IIa. Her father's phenotype was IIb, and mother's was type IV. The family phenotypes were consistent with familial combined hyperlipidaemia.

Bahrain Med Bull 1996;18(4):

Fibrinogen (Fg) is important in blood clotting following its conversion to fibrin by thrombin. Fibrin monomers polymerize in the presence of fibrin stabilising factor XIII, thus stabilising the fibrin clot. Fg is composed of three pairs of polypeptide chains ( $\alpha$ ,  $\beta$  and  $\gamma$ ) covalently linked at their amino terminal portions, forming a central area called the E domain; were thrombin acts. The carboxy terminal portions of  $\beta$  and  $\gamma$  chains form the terminal D domain. The genes for all three constitutive polypeptide chains of Fg are found in close proximity on chromosome 4<sup>1</sup>.

Congenital afibrinogenaemia is a rare coagulation disorder characterized by the absence of plasma Fg measured by both clottable and immunologic assays<sup>2</sup>. In 1981, Girolami et al demonstrated a double hereditary pattern for congenital afibrinogenaemia, one autosomal recessive and the other autosomal intermediate<sup>3</sup>.

Presentation in the neonatal period includes excessive bleeding from the umbilical cord, continued bleeding following circumcision, recurrent mucocutaneous haemorrhages, but not as severe as the intramuscular or intra-articular bleeding typically associated with classic haemophilia.

-----

\* Department of Paediatrics  
\*\* Department of Internal Medicine  
\*\*\* Department of Laboratories  
King Hussein Medical Centre  
Amman - Jordan

As opposed to afibrinogenaemia, dysfibrinogenaemia represents the presence of a functionally abnormal Fg. Most individuals are either asymptomatic or suffer a mild-to-moderate haemorrhagic disorder; however, about 10 % are associated with thrombosis<sup>4</sup>. The confirmation of the diagnosis require discordant of functional Fg and its antigen concentration.

We report a 9 month old Jordanian girl discovered to have absent Fg on routine coagulation studies because of a right thigh ecchymoses associated with a raised total cholesterol and triglycerides levels. Investigation of three-generation relatives was undertaken to determine abnormalities of Fg, total cholesterol (TC), triglycerides (TG) and LDL-Cholesterol (LDL-C) and this showed a pattern consistent with familial combined hyperlipidaemia (FCHL).

In addition, the raised Fg level among hyperlipidaemics as compared to normolipidaemics, suggest a possible role of lipids in Fg metabolism.

## METHODS

Fg was measured by precipitation and functionally by thrombin clottable Fg<sup>5</sup>. Enzymatic methods standardised by the Center for Disease Control (CDC) in Atlanta, Georgia using the Abell-Kendall method were employed to quantify plasma total cholesterol and triglyceride levels with Abbott VP Super System Analyser, Abbott Laboratories, and Irving, Texas, USA. Agarose electrophoresis was performed on 0.5 % agarose gel in 60 mmol/L of barbital buffer, at a pH of 8.6 for 3 hours at 50 V 150 mA, visualised by trichloroacetic acid.

### Family Under Study

A 9 month old Jordanian girl was referred to our hospital because of right thigh ecchymoses. She was the product of a full term normal vaginal delivery. No history of abnormal umbilical cord stump exsanguination, or haemorrhage at ear piercing. No bruising or significant haemorrhagic episodes during infancy. Her initial coagulation screen revealed a thrombin time (TT) (normal < 17 seconds), activated partial thromboplastin time (APTT) (normal 22-37 seconds), and prothrombin time (PT) (normal 9-12 seconds) were all greater than 100 seconds. Reptilase time (RT) 40 seconds (normal 13-16 seconds). All the aforementioned tests were corrected with control plasma. Clottable Fg was absent (normal 1.5-3.5 g/L) and no Fg could be detected by immunoprecipitation confirming the complete absence of Fg. An agarose gel electrophoresis visualised by trichloroacetic acid precipitation (Fig 1) showed absent Fg from the patient plasma. A prominent Fg band was found in the control plasma protein electrophoresis of her parents between  $\mu$  and  $\zeta$  region (Fig 1). An interesting feature was the prolonged bleeding time (BT) (Ivy template) of 10 minutes (normal 3-8 minutes) in the absence of thrombocytopenia, denoting platelets aggregation abnormality (platelets aggregation by ADP was 40 %, normal > 70 %), which did correct with the addition of fresh frozen plasma (FFP). Local therapy with ice packs and limiting her activity, in addition to FFP controlled the bleeding.

The parents were not related, and were asymptomatic regarding excessive bleeding. Their BT, PT, APTT, TT, RT and platelets aggregation studies were normal. Assays of parental Fg were; father 3 g/L, mother 2.8 g/L (normal 1.5-3.5 g/L). Absence of Fg from the patient plasma with normal parental values suggests autosomal recessive inheritance. The mean Fg levels in the normolipidaemic individuals were comparable to a reference population<sup>6</sup>, while the mean Fg levels in the hyperlipidaemic individuals were raised.

Because of increased incidence of coronary heart disease among the family of our patient, and considering Fg and hyperlipidaemia as risk factors for increased cardiovascular morbidity and mortality, a three-generation family study was undertaken (Fig 2). A total of 23 individuals have been studied, including all living grand parents, parents and parental siblings. On the paternal side all members were asymptomatic regarding excessive bleeding tendencies, two members (I-1, II-1) are known to have had myocardial infarction at the ages of 65, 54 respectively. On the maternal side all members were also asymptomatic regarding excessive bleeding tendencies, three members (I-3, I-4, II-8) were known to have had myocardial infarction at the ages of 58, 55, 45 years respectively, one of which was fatal (I-3) at the age of 58 years.

The results of the lipid studies were classified according to the WHO Classification of Hyperlipidaemias<sup>7</sup> and were as follows: phenotype IIa raised (TC/LDL-C) and normal TG (I-1, II-2, III-2, III-6); phenotype II<sub>b</sub> raised (TC/LDL-C/TG) (II-1, II-4, II-8, III-15); phenotype IV, normal (TC/LDL-C), raised TG, phenotype V, normal (LDL-C) raised (TC/TG) (III-a, III-8, II-5, III-10, III-14). Father's phenotype was II<sub>b</sub> while her mother's phenotype was IV. The results of the 23 individuals studied in the family are shown in Table 1.

Table 1. The age, gender, fibrinogen, total cholesterol, LDL cholesterol and triglycerides values according to the WHO classification for lipids in addition to the mean value for each group

	Age/Sex Year	Fibrinogen 1.5-3.5 g/L	Total Ch <5.2 mmol/l	TG <1.8 mmol/L	LDL-Ch 1.3-4.9 mmol/L
Patient III-9	9 months	0	6.12	1.22	5.09
<b>Hypercholesterolaemia (Type IIa), n=4</b>					
I-1	76y/M	3.6	7.16	2.63	5.81
II-2	58y/M	4.0	9.77	1.81	8.04
III-2	34y/M	3.8	18.04	2.00	15.22
III-6	29y/M	3.3	13.54	2.11	11.32
Mean $\pm$ SD	49 $\pm$ 10.10	4.10 $\pm$ 2.14	0.35 $\pm$ 12.13	4.73 $\pm$ 3.68	0.3 $\pm$ 22
<b>Hypertriglyceridaemia (Type IV/V), n=5</b>					
II-5/Mother	22y	2.8	4.65	3.16	3.7
III-1	36y/F	4.1	3.31	2.20	2.64
III-8	14y/M	3.8	4.34	2.45	3.72
III-10	28y/F	3.6	3.05	2.12	2.25
III-14	4y/F	2.7	2.66	2.45	2.14
Mean $\pm$ SD	21 $\pm$ 2.89	0.77 $\pm$ 2.48	0.41 $\pm$ 3.60	0.85 $\pm$ 3.4	0.62 $\pm$ 14
<b>(Type IIb), n=4</b>					
II-1	60y/M	3.8	11.68	2.46	9.84
II-4/father	28y	3.0	6.56	4.52	4.63
II-8	58y/M	4.2	9.51	8.69	8.06
III-15	42y/M	3.6	8.53	6.84	7.70
Mean $\pm$ SD	47 $\pm$ 7.56	2.16 $\pm$ 5.63	2.71 $\pm$ 7.93	2.50 $\pm$ 3.65	0.5 $\pm$ 15
<b>Normolipaemic n=10</b>					
I-2	72y/F	3.8	4.32	1.73	3.18
II-3	48y/F	3.5	5.71	1.69	4.67
II-6	52y/M	4.6	4.65	2.36	3.36
II-7	37y/M	3.0	4.42	1.39	2.79
III-3	33y/M	3.6	4.57	1.59	1.55
III-4	31y/F	3.8	6.15	1.71	4.39
III-5	27y/M	3.1	3.18	1.25	2.27
III-7	20y/F	3.0	4.65	1.29	4.08
III-12	8y/M	3.0	3.18	1.10	2.09
III-17	35y/M	3.0	5.50	1.29	4.44
Mean $\pm$ SD	36 $\pm$ 3.28	1.10 $\pm$ 1.54	0.36 $\pm$ 4.63	0.98 $\pm$ 2.43	0.49 $\pm$ 18

## DISCUSSION

In our report, we describe the coexistence of two genetic disorders in kindred, one related to Fg and the other to lipids.

Fg levels are controlled by an interaction between genetic and environmental factors<sup>8</sup>. Genetic control in normal individuals has been reported to range from as low as 15 % to as high as 51 %<sup>9</sup>. In afibrinogenaemia, the genetic defect is not due to an abnormality of the fibrinogen gene since copy for all three peptides has been reported to be present and grossly intact<sup>10</sup>. Consequently, the failure to synthesise/secretate Fg may be due to transcription, translation, and/or secretory defects.

A presumptive diagnosis of FCHL was made based on the demonstration of multiple phenotypes within the same family. Lipoprotein kinetic studies have indicated that high production rates of very low density lipoprotein (VLDL) and apolipoprotein B (apo-B) from the liver or abnormal 'metabolic channeling' in the circulation may underlie FCHL.

In addition, the AI-CIII-AIV gene cluster is the major locus for FCHL, and that mutation of the X2 allele found in half of all patients with FCHL accounts for the metabolic disorder<sup>11</sup>. The mean Fg levels in the hyperlipidaemic individuals were raised, as opposed to normal mean Fg levels in the normolipidaemic population. Fg levels correlated with TC in an epidemiological study<sup>12</sup>, also showed raised Fg in hyperlipoproteinaemia (HLP) type II<sup>13</sup>.

#### CONCLUSION

The association of two independent risk factors for coronary artery disease is described in kindred. The mean fibrinogen levels in hyperlipidaemic phenotypes were raised, while the mean fibrinogen levels in normolipidaemic were comparable to a reference population.

The mode of inheritance for familial combined hyperlipidaemia is dominant with reduced penetrance. The hereditary transmission of afibrinogenaemia is suggestive of autosomal recessive pattern. It may be possible to speculate on the possible protective role for hyperlipidaemia in patients with low fibrinogen levels.

#### REFERENCES

1. Henry I, Uzan G, Weil D, et al. The genes coding for A alpha, B beta- and gamma-chains of fibrinogen map to 4q2. *Am J Hum Genet* 1984;36:760-8.
2. Girolami A, De Marcol, Dal Bo Zanon R, et al. Rarer quantitative and qualitative abnormalities of coagulation. *Clin Haematol* 1985;14:385-411.
3. Girolami A, Cappellato G, Falezza G, et al. Demonstration of a double hereditary pattern for congenital afibrinogenemia. *Blut* 1981;44:249-56.
4. Lijnen HR, Soria J, Soria C. Dysfibrinogenemia (Fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation. *Thromb Haemost* 1984;51:108.
5. *Manuals of Laboratory Operations. Lipid and lipoprotein analysis.* Bethesda, MD: National Institute of Health. US Department of Health, Education and Welfare Publication. NIH 75-628. 1974;1:9-59.

6. Alaupovic P, McConathy WJ, Fesmire J, et al. Profiles of apolipoproteins and apolipoprotein B- containing lipoprotein particles in dyslipoproteinaemias. Clin Chem 1976;66:43-52.
7. Beaumont L, Carlson LA, Cooper G, et al. Classification of hyperlipidaemia and hyperlipoproteinaemias. Bull World Health Organ 1970;43:891-908.
8. Meade TW, Chakrabarti R, Haines AP. Characteristics affecting fibrinolytic activity and fibrinogen concentrations. Br Med J 1979;1:153-6.
9. Hamsten A, Iselins L de Faire U, et al. Genetic and cultural inheritance of plasma fibrinogen concentration. Lancet 1987;2:988-91.
10. Uzan G, Courtois G, Besmond C, et al. Analysis of fibrinogen genes in patients with congenital afibrinogenaemia. Biochem Biophys Res Commun 1984;120:376-83.
11. Wojciechowski AP, Farrall M, Cullen P, et al. Familial combined hyperlipidaemia linked to the apolipoprotein AI-CIII-AIV gene cluster on chromosome 11q23-q24. Nature 1991;349:161-4.
12. Korsan-Bengtzen K, Wilhelmsen L, Tibblin G. Blood coagulation and fibrinolysis in a random sample of 788 men 54 years old. Thromb Diath Haemorrh 1972;28:89-98.
13. Kowe GDO, Drummond MM, Third JLHC, et al. Increased plasma fibrinogen and platelet-aggregates in type II hyperlipoproteinaemia. Thromb Haemost 1979;42:1053-7.